{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-230926","form_type":"8-K","ticker":"MAZE","cik":"0001842295","company_name":"Maze Therapeutics, Inc.","filed_at":"2025-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.762476+00:00","generated_at":"2026-05-17T04:37:27.076529+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Maze appoints ex-Incyte CEO Hervé Hoppenot as Chairman, effective Oct 6","bullets":["Hervé Hoppenot appointed Class II director and Chairman of the Board, succeeding Charles Homcy, who remains a director.","Hoppenot served as Incyte CEO (2014-2025) and Chairman (2015-2025); also on boards of Bicycle Therapeutics and Laboratoires Pierre Fabre.","Receives pro rata portions of $40k director retainer and $30k Chairman retainer; granted option for 36,000 shares vesting over 36 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-230926","json":"https://secwatch.observer/filing/0001193125-25-230926.json","markdown":"https://secwatch.observer/filing/0001193125-25-230926.md","text":"https://secwatch.observer/filing/0001193125-25-230926.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842295/000119312525230926/0001193125-25-230926-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842295/000119312525230926/d84372d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:37:27.076529+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}